MI3 Market Alert: Building the largest hydroponic facility for the cannabis sector

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on FSD Pharma Inc. (CSE: HUGE | OTCQB: FSDDD) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on FSD Pharma Inc.

  • FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis.
  • FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its full Sale for Medical Purposes license on June 21, 2019.
  • Only 7M Outstanding, consolidating after rollback
  • RSI at 33 definitely near OVERSOLD territory
  • recent rebound from $4.40 to $9.20
  • HUGE traded over 2.3 Million shares since rollback on Oct 16
  • Support: S2; $ 6.35    S1; $ 7.50   Resistance:   R1; $7.70   R2; $8.15

About FSD Pharma

FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis. The Company is licensed to cultivate cannabis in approximately 25,000 square feet.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its full Sale for Medical Purposes license on June 21, 2019. FV Pharma intends to cover all aspects of the cannabis industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.




Herchak on how FinCanna offers investors a way to invest in top quality private cannabis companies

“FinCanna is diversified by investing in four companies to date. We have enough money for a fifth investment. We are diversified both geographically in California and across a number of different sectors. We invest in private companies. If you want to invest in top quality private companies the only way to invest in them directly is through us.” States Andriyko Herchak, CEO and Director of FinCanna Capital Corp. (CSE: CALI | OTCQB: FNNZF), in an interview with InvestorIntel’s Tracy Weslosky.

Andriyko went on to say that FinCanna is focused on the US with a primary focus on California, the largest cannabis market in North America. Andriyko also provided an update on FinCanna’s portfolio companies. He said that FinCanna’s four portfolio companies include QVI, ezGreen Compliance, Refined Resin and CTI. All the companies are startups in different stages of growth. QVI is the last company that FinCanna invested in and is expected to produce royalty this quarter. ezGreen Compliance is a Point-of-Sale software compliance firm that has signed a large client in California.

To access the complete interview, click here

Disclaimer: FinCanna Capital Corp. is an advertorial member of InvestorIntel Corp.




Do you know who the only cannabis company with sales in the US, Canada, and Europe is?

For investors wanting broad cannabis sector exposure with one of the fastest-growing cannabis companies globally (with rapid revenue growth), this one is for you.

TerrAscend Corp. (CSE: TER | OTCQX: TRSSF)  is “the first North American operator with scale operations in both Canada and the US….(and) the first and only cannabis company with sales in the US, Canada, and Europe.” By participating in the medical and legal adult-use cannabis market across Canada and in several legalized US states, where cannabis is used for therapeutic or adult-use, TerrAscend provides quality products, brands, and services to the global cannabinoid market.

Let’s start with some numbers for the cannabinoid market. Presently the potential for clients in Canada is 37 million, 327 million in the US, and 279 million in Europe.

TerrAscend businesses operations

  • The Apothecarium – An award winning cannabis dispensary with several retail locations in California and Nevada.
  • Arise Bioscience Inc. – A manufacturer and distributor of hemp-derived products.
  • Ilera Healthcare – Pennsylvania’s premier medical marijuana cultivator, processor, and dispenser.
  • Ascendant Laboratories Inc. – A biotechnology and licensing company committed to the continuous improvement of cannabinoid expressing plants.
  • Solace RX Inc. – A proposed Drug Preparation Premises (DPP) focused on the development of novel formulations and delivery forms.
  • Valhalla Confections – A manufacturer of premium cannabis-infused edibles.
  • (A vertically integrated medical cannabis operation in the making) – TerrAscend has been chosen by the state of New Jersey to be one of six permit applicants for a vertically integrated medical cannabis operation.

Looking at the above businesses owned by TerrAscend it is clear they have a very broad and rapidly growing exposure to the legal cannabinoid market. In a highly fragmented market with significant opportunity for consolidation and a strong emphasis on innovation and R&D, TerrAscend is developing world-class licensed intellectual property for commercialization, and amplifying revenue opportunities (as discussed below).

The GMP certified indoor cannabis facility tripling of expansion is approved

In the first week of October, TerrAscend Corp. received approval from Health Canada for significant expansion at its facility in Mississauga, Ontario. This will increase the licensed space at the facility nearly three-fold from 17,800 sq. ft. to 51,800 sq. ft. It will include a greater cultivation capacity, a commercial kitchen, formulation rooms and increased primary and secondary packaging capacity to allow for new product formats and extracts for the Canadian Cannabis 2.0 market. The 2.0 market relates to cannabis edibles, beverages, and vapes.

Michael Nashat, CEO of TerrAscend stated: “Achieving this approval milestone is a crucial step in our plan to cultivate premium grade cannabis at scale for distribution to the EU and other international markets.”

The GMP certified indoor cannabis facility was first licensed for cultivation in July 2017. The expansion will serve as a platform for the export of cannabis products to Europe and other international jurisdictions.

Revenues on track to grow by 2,200% (pro forma) over the last 3 quarters

As an expanding U.S. Multi-State Operator (MSO) the Company is looking to capture an unprecedented market opportunity estimated at US$40 billion by 2024. Robust revenue growth is estimated to finish FY 2019 at ~C$135 million in revenue, up from only C$6.8 million in FY 2018. That would be a ~20 fold increase in just 1 year.

Adam Kozak CFO of TerrAscend comments: “As CFO of TerrAscend Corp. it has been exciting to lead TER to a global cannabis company with operations in both the U.S. and Canada, as well as distribution to Europe. We have been executing on our U.S. expansion strategy and organic initiatives, which have resulted in over 2,200% growth over the last 3 quarters (on a pro forma basis).”

TerrAscend is on track to achieve a 2,200% (pro forma) revenue growth

2019 will certainly see incredible revenue growth, which should continue in 2020 and 2021. Revenues are forecast to grow significantly to reach C$364 million in 2020, and $480 million in 2021. TerrAscend is forecast to become profitable in 2020, with a forecast C$17.1 million of net profit.

Management

The TerrAscend leadership team has a proven track record in life sciences with deep roots in pharmaceutical and medical industries, with a lifelong dedication to consumer health.

TerrAscend is based in Canada and is now serving a growing global market and has surging revenue growth. TerrAscend’s growth strategy should see them as a big winner in the fast-growing global cannabinoid industry. TerrAscend has a market cap of C$ 271.5 million, and an average analyst price target of C$9.00 representing ~80% upside.




A technology incubator that offers a green sky for the cannabis industry

The cannabis sector will soon get another boost. New cannabis products such as edibles, beverages, topicals and extracts will become legal to sell in Canada in mid-December 2019. Added to that is continued progress on the legalization of cannabis use globally. The following countries are all moving towards cannabis legalization and any could be next – USA, Jamaica, Czech Republic, Colombia, Peru, The Netherlands, Portugal, Spain, Iceland and France. All this change leads to innovation. In particular better ways to extract and consume cannabis, especially for medicinal purposes.

Green Sky Labs Inc. (GSL) is a technology incubator for the cannabis industry with five business verticals that are currently being commercialized. By bringing capital and superior science and technologies, GSL is improving the current standards of cannabis extraction. With a common goal, the focus for the Company’s team of experienced business professionals, entrepreneurs, doctors, professors, researchers and administrators is clear: To drive innovation, better products, and better outcomes in the cannabinoid industry, from plant to patient and all stages in between.

Green Sky Labs five business verticals that are currently being commercialized

1) Kalmex Inc. (Membrane-based extraction technology)

With their strategic partners, PetroSep Corporation and Kayzan Holdings, GSL has formed a new company, Kalmex Inc., to commercialize the membrane technology licensed to GSL by PetroSep. Kalmex is in the design and planning stages of building its initial facility in California, targeting production in Q4 2020. At full capacity Kalmex’s anticipated 5 tonne feed extraction facility is expected to harvest approximately 10 acres of biomass on a daily basis. With outdoor grown hemp being more robust, significantly cheaper and more widely available than marijuana, it will be highly complementary to Kalmex’s large scale technology.

2) Trichome Agronomy (Manitoba hemp)

By leveraging its relationship with the Manitoba government and its hemp processing research GSL is developing an opportunity in the hemp industry. The Company has contracted local farmers in Manitoba to grow 4,200 acres of hemp using high CBD yielding hemp varieties. The Company anticipates its new processing facility will be completed in January 2020 and begin to generate cash flow shortly thereafter.

3) Nectar Health Sciences (Cannabinoid isolation technology)

Nectar Health Sciences was formed in the Spring of 2019 as a new subsidiary to commercialize proprietary, chemistry-based cannabinoid isolation technology. Several recent breakthroughs have made the process scalable for commercialization. Detailed engineering of a commercial system has commenced with the first commercial operation expected by Q3 2020 in Western Canada.

4) My Pain Sensei (Chronic pain)

Green Sky Labs Chronic Pain Partnership collaboration with IBM Watson has created a disruptive solution to address how chronic pain is diagnosed, treated and managed. My Pain Sensei is a web portal and mobile application for the management of chronic pain. It operates as a real time, diagnostic, analysis and treatment tool for the public and medical community.

5) Viscuris (Cannabinoid pharmaceutical)

GSL has a 50% equity share in Viscuris, a cannabinoid pharmaceutical venture. The other partner is the International Center for Cannabis Therapy (ICCT). Based in Prague Czech Republic, ICCT has over 70 scientists conducting cannabinoid research. Viscuris will be introducing cannabis-based health & wellness products to global markets as well as conducting clinical trials for high-value indications.

Conclusion

This continuing revolution has come from the education and understanding of the many uses that cannabinoids and hemp based products give. In Canada, both “cannabis” and “industrial hemp” are legal for medical and recreational uses at the federal level. The exploding cannabis market in Canada will also soon mean licensed vendors can sell cannabis edibles, oils and tinctures. New estimates from cannabis industry analysts forecast the hemp-CBD market alone could hit $22 billion by 2022.

Unlike THC, the chemical compound that gives weed its signature effect, CBD has been shown to help with everything from PTSD and anxiety, to MS and epilepsy, without getting you high. The day is coming when your Doctor will prescribe a CBD product to ease your pain, or for other health reasons such as Parkinsons or Motor Neuron Disease, and other severe neuralgic conditions, to name just a few.

Green Sky Labs Inc. is at the forefront of innovation and commercialization, and with so much happening will be sure to remain on investor’s radar. The Company is currently private and has been financed mostly by private placements.




MI3 Market Alert: Taking health, wellness and CBD products to another level

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on Relevium Technologies Inc. (TSXV: RLV | OTCQB: RLLVF) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on Relevium Technologies Inc.

  • Relevium operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis.
  • Relevium operates through two wholly owned subsidiaries: BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com. Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.
  • RSI flirting near OVERSOLD territory …. Possible rebound!!!
  • Support: S2; $0.045   S1; $0.05   Resistance:   R1; $0.065     R2; $0.08

About Relevium Technologies

Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:

BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.

Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.




SOL Global has a new name Bluma Wellness Inc., and a new focus to become profitable

SOL Global Investments Corp. (CSE: SOL) will be having a special meeting of common shareholders on October 15, 2019 where they will be asked to consider and approve the proposed change of business from an international cannabis investment company, to that of a U.S. multi-state cannabis operator (MSO) under the Life Sciences category of the Canadian Securities Exchange (CSE). In connection with the Company’s proposed change of business shareholders will also be asked to consider and approve a change of name of the Company to “Bluma Wellness Inc.”.

SOL Investment Group (SIG) will be spun out of SOL Global and operate completely independent of Bluma Wellness and HeavenlyRx. SOL Global intends to spin off all of SOL Global’s non-multi-state cannabis operator (MSO) assets not under the Bluma Wellness umbrella to SIG. Further details of the spin-off transaction will be provided in the coming weeks as the Company works to conclude its strategic review of its assets. The purpose is to fully reflect the value of the different assets. Andrew DeFrancesco will lead the newly formed SOL Investment Group (SIG) and step down from his roles as Chairman & CIO of SOL Global.

SOL Global to focus on the US states of Florida, Michigan and California and on being more profitable

Initial operations for SOL Global will include assets in three of the top ten cannabis revenue markets in the U.S; namely Florida, Michigan and California. The new Company strategy is also to be more profitable by keeping the capital and operating expenses low with an efficiency-driven model of integrating operations and streamlining.

The timing of the proposed change of business is strategic, as SOL Global CEO Brady Cobb commented: “One of the innate strengths of SOL Global’s management is knowing when to enter a market, as is evidenced with our early success in Canada and Florida. We have planned this transition and the market entrance of our MSO to coincide with the rapid growth of the legal U.S. cannabis marketplace amid a presumptive tail wind from federal policy reform initiatives related to cannabis.”

Bluma Wellness – Everyone to “bloom”

The Company’s proposed change of name to Bluma Wellness Inc. was selected to ensure that patients and consumers utilizing SOL Global’s plant-based products can enhance their daily lives, namely to bloom and thrive. Bluma is an ancient Hebrew word which means to flower, bloom or blossom.

Mr. Cobb adds: “We chose the name Bluma Wellness as an appropriate way to honor the true intent of each seed that we cultivate, harvest, and deliver as a product.”

SOL plans to complete previously announced acquisitions. This will include the licensed dispensaries operated by MCP Wellness in Michigan (April 24, 2019), California based acquisitions which include the famed Humboldt, cultivator “Northern Emeralds” and dispensary chain “One Plant USA” (May 16, 2019). The resulting products of the new combined company Bluma Wellness will be powered by Northern Emeralds’ genetics cultivation and processing techniques that will be anchored by the brands and products that SOL Global has invested in. The product will then be deployed by dispensaries that include One Plant’s robust retail arm across the states of Florida, Michigan, and California.

Some of the SOL Global’s portfolio of investments 

Note: Added to above is also PRØHBTD, which is a media platform built exclusively to create, develop and market cannabis brands to global audiences. Also a ~42% stake in Heavenly Rx Ltd, and an alliance with the University of Miami.

Despite market volatility, SOL Global is holding to its strategic direction and has continued to make additional investments in the cannabis, CBD and hemp sectors. The Company’s renewed focus is on the key US states of Michigan, California, and Florida. SOL is also investing in operational upgrades to efficiently scale up operations to expedite the path to profitability for the newly named Bluma Wellness, which they expect will ultimately deliver value to shareholders. SOL Global certainly has firm plans to bloom in a new name, and now a whole new structure.

SOL Global Investments Corp. is headquartered in Toronto Canada; and has a market cap of C$ 70 million.